Table 1.
Baseline and demographic characteristics of study population with coronary artery aneurysms.
| Studied population (N = 100) | Conservative approach (N = 47) | Invasive approach (N = 53) | p-value | |||
| PCI (N = 42) | CABG (N = 11) | |||||
| Age (years) | 64.9 12.6 | 66.1 11.3 | 64.8 14.2 | 60 10.7 | 0.364 | |
| BMI (kg/) | 27.4 5.3 | 27.6 5.8 | 26.8 4.8 | 28.9 4.9 | 0.464 | |
| LVEF (%) | 52.3 10.4 | 52.7 12.2 | 51.4 9.1 | 54.2 5.8 | 0.276 | |
| Women (n, %) | 18 (18) | 8 (17) | 9 (21.4) | 1 (9.1) | 0.810 | |
| Dyslipidemia (n, %) | 52 (52) | 20 (42.6) | 25 (59.5) | 7 (63.6) | 0.199 | |
| Diabetes mellitus (n, %) | 25 (25) | 10 (21.3) | 10 (23.8) | 5 (45.5) | 0.256 | |
| Hypertension (n, %) | 62 (62) | 30 (63.8) | 24 (57.1) | 8 (72.7) | 0.611 | |
| Smoking (n, %) | 28 (28) | 9 (19.1) | 15 (35.7) | 4 (36.4) | 0.171 | |
| Chronic kidney disease (n, %) | 34 (34) | 18 (38.3) | 12 (28.6) | 4 (40) | 0.589 | |
| Significant CAD (n, %) | 78 (78) | 30 (63.8) | 37 (88.1) | 11 (100) | 0.003 | |
| Single-vessel disease (n, %) | 30 (30) | 16 (34) | 14 (33.3) | 0 (0) | 0.05 | |
| Two-vessels disease (n, %) | 29 (29) | 12 (25.5) | 14 (33.3) | 3 (27.3) | ||
| Three-vessels disease (n, %) | 19 (19) | 2 (4.3) | 9 (21.4) | 8 (72.7) | ||
| Type of CAA (n, %) | 0.548 | |||||
| Fusiform | 54 (50) | 27 (52.9) | 22 (48.9) | 5 (41.7) | ||
| Saccular | 54 (50) | 24 (47.1) | 23 (51.1) | 7 (58.3) | ||
| Longitudinal aneurysm diameter (mm) | 10.4 6.4 | 10.7 6.6 | 10.2 6.7 | 9.7 4 | 0.276 | |
| Transverse aneurysm diameter (mm) | 7.2 2.2 | 7.4 2 | 6.7 1.9 | 8.5 2.8 | 0.039 | |
| Giant CAA (n, %) | 21 (19.4) | 13 (25.5) | 4 (8.9) | 4 (33.3) | 0.042 | |
| Involved coronary (n, %) | 0.051 | |||||
| LAD | 36 (36) | 21 (44.7) | 11 (26.8) | 4 (36.4) | ||
| RCA | 34 (34) | 11 (23.4) | 20 (48.8) | 3 (27.3) | ||
| CX | 24 (24) | 12 (25.2) | 10 (24.4) | 2 (18.2) | ||
| LM | 5 (5) | 3 (6.4) | 0 (0) | 2 (18.2) | ||
| MACCE (n, %) | 13 (13) | 6 (12.8) | 6 (14.3) | 1 (9.1) | 1 | |
| Follow-up (months) | 46.2 24 | 47.1 24 | 47.3 23.7 | 38 25 | 0.495 | |
| Anti-thrombotic treatment (n, %) | 0.009 | |||||
| None | 5 (5) | 5 (10.6) | 0 (0) | 0 (0) | ||
| Aspirin or P2Y12- | 40 (40) | 21 (44.7) | 11 (26.2) | 8 (72.7) | ||
| Dual anti-platelet | 30 (30) | 10 (21.3) | 19 (45.2) | 1 (9.1) | ||
| Oral anticoagulant | 25 (25) | 11 (23.4) | 12 (28.6) | 2 (18.2) | ||
*BMI, body mass index; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; CAA, coronary artery aneurysm; LAD, left anterior descending; RCA, right coronary artery; CX, circumflex artery; LM, left main; MACCE, major adverse cardiac and cerebrovascular events.